Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms

Critical Care Medicine

Volumn 33, Issue 1, 2005, Pages 89-97

  Watanabe, Eizo ^a   Hirasawa, Hiroyuki ^a   Oda, Shigeto ^a   Matsuda, Kenichi ^a   Hatano, Masahiko ^a   Tokuhisa, Takeshi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Critical Care; Cytokines; Interleukin 1; Interleukin 6; Polymorphism (Genetics); Tumor Necrosis Factor

Indexed keywords

FLUORESCENT DYE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CRITICAL ILLNESS; DNA POLYMORPHISM; FEMALE; GEL ELECTROPHORESIS; GENE FREQUENCY; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TANDEM REPEAT; UNIVERSITY HOSPITAL; VOLUNTEER;

ADULT; AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; FEMALE; GENE FREQUENCY; HETEROZYGOTE DETECTION; HOSPITAL MORTALITY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SIALOGLYCOPROTEINS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12244252762     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000150025.79100.7D     Document Type: Article

References (42)

1. Baue AE, Durham R, Faist E: Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): Are we winning the battle? Shock 1998; 10:79-89
2. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
3. Stunff CL, Fallin D, Schork NJ, et al: The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. Nat Genet 2000; 26:444-446
4. Emonts M, Hazelzet JA, de Groot R, et al: Host genetic determinants of Neisseria meningitides infections. Lancet Infect Dis 2003; 3:565-577
5. Shapiro L, Gelfand JA: Cytokine and sepsis: Pathophysiology and therapy. New Horiz 1993; 1:13-22
6. De Beaux AC, Goldie AS, Ross JA, et al: Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996; 83:349-53
7. Stueber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24:381-384
8. Powel JJ, Fearon KCH, Siriwardena AK, et al: Evidence against a role for polymorphisms at tumor necrosis factor, interleukin-1 and interleukin-1 receptor antagonist gene loci in the regulation of disease severity in acute pancreatitis. Surgery 2001; 129:633-640
9. Schlueter B, Raufhake C, Erren M, et al: Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30:32-37
10. Gaudino M, Andreotti F, Zamparelli R, et al: The - 174G/C intrleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation: Is atrial fibrillation an inflammatory complication? Circulation 2003; 108 (suppl 2):II-195-II-199
11. Heesen M, Obertacke U, Schade FU, et al: The interleukin-6 G (-174) C polymorphism and the ex vivo interleukin-6 response to endotoxin in severely injured blunt trauma patients. Eur Cytokine Netw 2002; 13:72-77
12. Matsuda K, Hirasawa H, Oda S, et al: Current topics on cytokine removal technologies. Ther Apher 2001; 5:306-314
13. Van Zee KJ, DeForge LE, Fischer E, et al: IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol 1991; 146:3478-3482
14. Gebhard F, Pfetsch H, Steinbach G, et al: Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg 2000; 135:291-295
15. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
16. Vincent JL, De Mendonca A, Cantraine F, et al: Use the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Crit Care Med 1998; 26:1793-1800
17. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
18. Oda S, Hirasawa H, Sugai T, et al: Cellular injury score for multiple organ failure severity scoring system. J Trauma 1998; 45:304-311
19. Stueber F, Udalova IA, Book M, et al: -308 Tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996; 46:42-50
20. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376
21. Santtila S, Savinainen K, Hurme M: Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998; 47:195-198
22. Brull DJ, Montgomery HE, Sanders J, et al: Interleukin-6 gene -174G>C and -572G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21:1458-1463
23. Guo SW, Thompson EA: Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 48:361-372
24. Hirasawa H, Baue AE: Blood purification therapy to prevent or treat MOF. In: Multiple Organ Failure. Baue AE, Faist E, Fry DE (Eds). New York, Springer-Verlag, 2000, pp 501-504
25. Remick DG, Call DR, Ebong SJ, et al: Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 2001; 29:473-481
26. Panacek EA, Kaul M: IL-6 as a marker of excessive TNF-α activity in sepsis. Sepsis 1999; 3:65-73
27. Konrad R, Carola WL, Friedrich G, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-742
28. Remick DG, Bolgos GR, Siddiqui J, et al: Six at six: Interleukin-6 measured 6h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17:463-467
29. De Maio A, Mooney ML, Matesic LE, et al: Genetic component in the inflammatory response induced by bacterial lipopolysaccharide. Shock 1998; 10:319-323
30. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Nat Acad Sci U S A 1997; 94:3195-3199
31. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 24:18138-18144
32. Schroeder J, Kahlke V, Book M, et al: Gender difference in sepsis: Genetically determined? Shock 2000; 14:307-311
33. Heesen M, Bloemeke B, Heussen N, et al: Can the interleukin-6 response to endotoxin be predicted? Studies of the influence of a promoter polymorphism of the interleukin-6 gene, gender, the density of the endotoxin receptor CD14, and inflammatory cytokines. Crit Care Med 2002; 30:664-669
34. Ma P, Chen D, Pan J, et al: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002; 30: 1046-1050
35. O'Keefe GE, Hybki DL, Munford RS: The TNF G → A single nucleotide polymorphism at the -308 position in the tumor necrosis factor-α promoter increases the risk for severe sepsis after trauma. J Trauma 2002; 52:817-826
36. Yende S, Quasney MW, Tolley E, et al: Association of tumor necrosis factor gene polymorphisms and prolonged mechanical ventilation after coronary artery bypass surgery. Crit Care Med 2003; 31:133-140
37. Heesen M, Kunz D, Bachmann-Mennenga B, et al: Linkage disequilibrium between tumor necrosis factor (TNF)-α-308 G/A promoter and TNF-β NcoI polymorphisms: Association with TNF-α response of granulocytes to endotoxin stimulation. Crit Care Med 2003; 31:211-214
38. Schroeder O, Schulte KM, Ostermann P, et al: Heat shock protein 70 genotypes HSPA1B and HSPA1L influence cytokine concentrations and interfere with outcome after major injury. Crit Care Med 2003; 31:73-79
39. Waterer GW, ElBahlawan L, Quasney MW, et al: Heat shock protein 70-2 + 1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit Care Med 2003; 31: 1367-1372
40. Arnalich F, Garcia-Palomero E, Lopez J, et al: Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000; 68:1942-1945
41. Arend WP: The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13:323-340
42. Jones KG, Brull DJ, Brown LC, et al: Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103:2260-2265